Christiane Querfeld Selected Research

Mechlorethamine (Nitrogen Mustard)

7/2022	Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data.
5/2022	Correction to: The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma.
1/2022	Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides.
1/2022	Use of chlormethine 0.04% gel for mycosis fungoides after treatment with topical chlormethine 0.02% gel: A phase 2 extension study.
5/2021	The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma.
1/2021	Lack of Systemic Absorption of Topical Mechlorethamine Gel in Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma.
1/2021	A Little Experience Goes a Long Way: Chlormethine/Mechlorethamine Treatment Duration as a Function of Clinician-Level Patient Volume for Mycosis Fungoides Cutaneous T-Cell Lymphoma (MF-CTCL)-A Retrospective Cohort Study.
9/2020	Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christiane Querfeld Research Topics

Disease

23	Mycosis Fungoides 07/2022 - 07/2004
22	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 07/2022 - 09/2003
11	Neoplasms (Cancer) 01/2022 - 07/2005
9	Lymphoma (Lymphomas) 01/2022 - 12/2009
4	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 07/2006
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021 - 09/2013
3	Disease Progression 09/2013 - 01/2006
2	Dermatitis 07/2022 - 06/2018
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022 - 01/2021
2	Pruritus (Itching) 01/2019 - 12/2004
2	B-Cell Lymphoma (Lymphoma, B Cell) 06/2018 - 09/2013
2	Fatigue 02/2014 - 08/2011
1	Contact Dermatitis (Eczema, Contact) 01/2022
1	Exanthema (Rash) 08/2021
1	Triple Negative Breast Neoplasms 01/2021
1	Hodgkin Disease (Hodgkin's Disease) 01/2021
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Psoriasis (Pustulosis Palmaris et Plantaris) 06/2018
1	Eczema 06/2018
1	Sarcoidosis (Schaumann Disease) 07/2016
1	Bullous Pemphigoid (Pemphigoid) 01/2016
1	Graft vs Host Disease (Graft-Versus-Host Disease) 07/2015
1	Fibrosis (Cirrhosis) 12/2014
1	Pain (Aches) 02/2014
1	Confusion (Bewilderment) 09/2013
1	Sezary Syndrome (Sezary Erythroderma) 09/2011
1	Diarrhea 08/2011
1	Pityriasis Rubra Pilaris 08/2011
1	T-Cell Lymphoma (Lymphoma, T Cell) 06/2010
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 06/2010
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/2009
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 05/2007
1	Exfoliative Dermatitis (Erythroderma) 12/2004

Drug/Important Bio-Agent (IBA)

8	Mechlorethamine (Nitrogen Mustard)FDA Link 07/2022 - 09/2020
6	Biological ProductsIBA 11/2021 - 09/2003
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 09/2011
3	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2020
2	TTI-621IBA 11/2021 - 01/2021
2	Rituximab (Mabthera)FDA Link 01/2021 - 11/2019
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 02/2014
2	Lenalidomide (CC 5013)FDA Link 11/2019 - 02/2014
2	pembrolizumabIBA 11/2019 - 07/2016
2	Histone Deacetylase InhibitorsIBA 01/2019 - 07/2005
2	Monoclonal AntibodiesIBA 01/2016 - 07/2005
2	enzastaurinIBA 08/2011 - 07/2006
2	Interleukin-2 (IL2)IBA 04/2007 - 07/2005
2	Bexarotene (LGD1069)FDA Link 05/2006 - 07/2004
2	RetinoidsIBA 05/2006 - 07/2004
1	Ointments (Pastes)IBA 07/2022
1	Immune Checkpoint ProteinsIBA 01/2022
1	B7-H1 AntigenIBA 01/2022
1	Inducible T-Cell Co-Stimulator ProteinIBA 01/2022
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2022
1	Indicators and Reagents (Reagents)IBA 01/2022
1	dupilumabIBA 08/2021
1	mogamulizumabIBA 08/2021
1	cabazitaxel FDA Link 01/2021
1	NivolumabIBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2019
1	romidepsin (FK228)FDA Link 01/2019
1	Phosphotransferases (Kinase)IBA 11/2018
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2018
1	CytokinesIBA 01/2017
1	ChemokinesIBA 01/2017
1	Brentuximab VedotinIBA 12/2016
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 06/2016
1	AutoantibodiesIBA 01/2016
1	Complement System Proteins (Complement)IBA 01/2016
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 12/2014
1	MucinsIBA 12/2014
1	Glia Maturation Factor (GMF)IBA 09/2013
1	DNA (Deoxyribonucleic Acid)IBA 09/2011
1	MethyltransferasesIBA 09/2011
1	Temozolomide (Temodar)FDA LinkGeneric 09/2011
1	Sorafenib (BAY 43-9006)FDA Link 08/2011
1	Alemtuzumab (Campath)FDA Link 12/2009
1	InterleukinsIBA 04/2007
1	Annexin A5IBA 07/2006
1	Protein Kinase C betaIBA 07/2006
1	Propidium (Propidium Iodide)IBA 07/2006
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 07/2006
1	Capsules (Microcapsules)IBA 05/2006
1	Retinoid X Receptors (Retinoid X Receptor)IBA 05/2006
1	CytosineIBA 07/2005
1	GuanineIBA 07/2005
1	Ficusin (Psoralen)IBA 03/2005
1	Etanercept (Enbrel)FDA Link 12/2004
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 07/2004
1	Retinoic Acid Receptors (Retinoic Acid Receptor)IBA 07/2004

Therapy/Procedure

23	Therapeutics 05/2022 - 09/2003
5	Immunotherapy 01/2022 - 01/2017
2	Radiotherapy 09/2013 - 03/2013
1	Aftercare (After-Treatment) 01/2022
1	Injections 11/2021
1	Duration of Therapy 01/2021
1	Hematopoietic Stem Cell Transplantation 07/2015
1	Transplantation 07/2015
1	Drug Therapy (Chemotherapy) 09/2013
1	Photopheresis 10/2012
1	Subcutaneous Injections 04/2007